Does raw cannabis contain THC?

Very little, if any, in freshly harvested plant material. The plant biosynthesises THCA — the acid-form precursor — rather than THC directly. Decarboxylation (typically via heat) is required to convert THCA into THC. Small amounts of conversion do occur naturally over time at ambient temperatures, but the proportion in fresh material is generally very low.

What temperature is needed for decarboxylation?

Meaningful conversion of THCA to THC begins at roughly 100°C and proceeds more rapidly in the 110–145°C range, depending on duration and the nature of the substrate. It's a time-temperature relationship rather than a fixed threshold — lower temperatures require longer exposure to achieve comparable conversion. Above approximately 150–160°C, volatile terpenes begin to degrade significantly alongside the decarboxylation reaction.

Is THCA the same as THC pharmacologically?

No. THCA and THC are structurally distinct molecules with different three-dimensional shapes. THCA does not interact with CB1 receptors in the same way THC does, due in part to its bulkier carboxyl group. Researchers study the acid and neutral forms separately, and neither should be assumed to have the same pharmacological properties as the other. Active investigation into the acid-form cannabinoids continues in the scientific literature.

Why does decarboxylation matter for manufactured medicinal cannabis products?

In regulated pharmaceutical manufacturing, decarboxylation is a documented, validated step in the production process. The TGA's Good Manufacturing Practice (GMP) framework requires that conditions be controlled and recorded, and finished products are analytically tested to confirm their cannabinoid profile. This is what allows batch-to-batch consistency. Some formulations intentionally retain a proportion of acid-form cannabinoids — that too is a deliberate manufacturing decision confirmed by testing.

Do all cannabinoids have acidic precursors that require decarboxylation?

Most of the major and minor cannabinoids do originate from acid-form precursors in the plant. CBDA converts to CBD, CBGA to CBG, and so on across the family. CBN is a notable exception — it is primarily an oxidative degradation product of THC rather than a direct decarboxylation product, and forms through a different pathway involving exposure to heat, light, and oxygen over time.

Decarboxylation Explained

By Tom Whitfield · 24 June 2026 · 7 min read

a man holding a pen and looking at a computer screen

The chemical step most people skip over

Freshly harvested cannabis contains almost no tetrahydrocannabinol (THC). That tends to surprise people. What the plant actually produces is THCA , tetrahydrocannabinolic acid , along with its acidic cousins like CBDA and cannabigerolic acid (CBGA). These are structurally distinct from the cannabinoids most researchers study, and converting one into the other requires a specific chemical transformation: decarboxylation.

It's a single reaction, well understood in organic chemistry, and yet it sits at the centre of almost everything relevant to how cannabinoid preparations are made. Worth understanding properly.

What decarboxylation actually is

The word comes from the Latin carboxyl , the -COOH functional group hanging off the acid-form cannabinoid molecule. Decarboxylation is simply the removal of that carboxyl group as carbon dioxide (CO₂). What remains is a neutral, non-acid cannabinoid with a different molecular weight and, critically, a different three-dimensional shape.

In chemical notation: THCA loses a CO₂ molecule and becomes THC. CBDA loses CO₂ and becomes CBD. CBGA; often described as the precursor cannabinoid from which many others derive, follows the same pattern. The reaction is thermally driven: heat supplies the activation energy needed to break that C–C bond and release the gas.

It also happens slowly at room temperature over time, which is partly why aged plant material tends to have higher proportions of neutral cannabinoids than freshly harvested flower. But slow ambient conversion is inefficient and unpredictable. Controlled heat is what makes it reliable.

The temperature and time relationship

This is where the chemistry gets genuinely interesting, and also where a lot of informal information falls apart. Decarboxylation is not a single threshold event, it's a time-temperature function. You can run the reaction at a lower temperature for longer, or at a higher temperature for a shorter period. Both can achieve comparable conversion, but the trade-offs differ.

Research published in journals indexed on PubMed; including work from the Netherlands referenced by the Bedrocan group, has mapped decarboxylation kinetics for cannabis in some detail. In broad terms, THCA begins converting meaningfully above approximately 100°C, with substantial conversion occurring in the 110–145°C range over periods of 30–90 minutes depending on the substrate and preparation method. Push past 150–160°C and you start accelerating the degradation of other compounds: the volatile terpenes are the first to go.

That last point matters for anyone thinking about the full chemical picture of a preparation. Terpenes like myrcene, limonene, and linalool have boiling points well below the temperatures used for vigorous decarboxylation. High-heat, short-duration approaches optimise for cannabinoid conversion; lower-heat, longer approaches may preserve more of the volatile fraction. The right balance depends on what the preparation is ultimately for, and that's a decision for formulation chemists and pharmacists, not something an end-user should be guessing at.

Why the molecular shape change matters

The reason any of this is pharmacologically relevant comes down to receptor geometry. The endocannabinoid system; a broadly distributed signalling network with receptors in neural tissue, peripheral organs, and immune cells, operates through precise lock-and-key interactions. The CB1 receptor, concentrated heavily in the central nervous system, has a binding pocket shaped to accommodate certain molecular geometries. THCA, with its bulkier carboxyl group, does not fit that pocket in the same way.

After decarboxylation, the resulting THC molecule adopts a conformation that allows it to interact with CB1 in a way THCA does not. This is why the pharmacological properties of the acid-form and the neutral form are studied separately, they behave differently in biological systems, and neither should be assumed to have the same properties as the other. Some researchers are actively investigating the acid forms on their own terms, but that's a separate question from the role of decarboxylation in producing the neutral cannabinoids.

CBD; the decarboxylated product of CBDA, has a different binding profile again. It shows relatively low affinity for CB1 and CB2 in direct binding assays, and much of the research into its pharmacology focuses on other molecular targets. The point is the same though: decarboxylation is the chemical prerequisite for the neutral cannabinoid to exist at all.

Decarboxylation in regulated pharmaceutical preparations

In Australia, medicinal cannabis products that require a prescription are accessed under pathways set out by the Therapeutic Goods Administration (TGA): the Special Access Scheme and the Authorised Prescriber framework, among others. Products on the Australian Register of Therapeutic Goods (ARTG) and those supplied under the SAS Category B pathway are required to meet manufacturing standards, most commonly the TGA's Good Manufacturing Practice (GMP) requirements.

For a manufactured oil or capsule, decarboxylation is one step in a documented, validated manufacturing process. The conditions; temperature, duration, atmosphere, substrate water content, are controlled and recorded. Analytical testing will confirm the cannabinoid profile of the final product, showing THC and CBD concentrations alongside residual acid-form cannabinoids. Some preparations intentionally retain a proportion of THCA or CBDA if that's the target profile.

This is worth knowing because it explains why batch-to-batch consistency is possible in a pharmaceutical context and much harder to achieve otherwise. Decarboxylation under uncontrolled conditions produces variable results.

What happens to the minor cannabinoids

The same chemistry applies across the cannabinoid family. CBG comes from decarboxylation of CBGA. Cannabichromene (CBC) and cannabidivarin (CBDV) both have acidic precursors that undergo the same reaction. Even some of the less commonly discussed cannabinoids, including CBN, which is primarily an oxidative degradation product of THC rather than a direct decarboxylation product; exist downstream of thermal and oxidative processes applied to the starting acid-form material.

And in a full-spectrum preparation, the goal is typically to preserve the whole constellation of cannabinoids and terpenes through processing, including appropriate decarboxylation of the acid forms, so that the resulting product reflects the chemical complexity of the starting material. That's quite different from an isolate, where a single cannabinoid is purified away from everything else.

I'll admit I spent longer than I should have a couple of years ago trying to track down consistent kinetic data on CBDA decarboxylation specifically. The literature is thinner than for THCA. It's the kind of gap that turns up when you're building a reference file; a reminder that the evidence base for individual minor cannabinoids is still catching up to the research on the major ones.

A note on bioavailability and what comes after

Decarboxylation produces the neutral cannabinoid, but that's just the starting point for what happens in the body. How well any cannabinoid is actually absorbed depends on pharmacokinetics, the absorption, distribution, metabolism, and elimination processes, and on the formulation itself. An oil-based preparation will behave differently from a water-soluble emulsion or a sublingual spray. First-pass metabolism in the liver is a significant consideration for oral preparations.

All of that is a separate conversation from the chemistry of decarboxylation itself. But it's worth flagging here because decarboxylation is sometimes treated as the entire story; as if producing THC from THCA is the endpoint. It isn't. It's the chemical step that makes the active cannabinoid available; what happens to it from there is determined by biology and formulation science.

Honestly, the chemistry isn't complicated once you see it laid out. It's one bond breaking, one small molecule leaving. But the downstream implications, for manufacturing, for regulation, for pharmacology, are worth taking seriously.

Sources

, Tom Whitfield, Health librarian, references & fact-checking

Common questions

Does raw cannabis contain THC?: Very little, if any, in freshly harvested plant material. The plant biosynthesises THCA — the acid-form precursor — rather than THC directly. Decarboxylation (typically via heat) is required to convert THCA into THC. Small amounts of conversion do occur naturally over time at ambient temperatures, but the proportion in fresh material is generally very low.
What temperature is needed for decarboxylation?: Meaningful conversion of THCA to THC begins at roughly 100°C and proceeds more rapidly in the 110–145°C range, depending on duration and the nature of the substrate. It's a time-temperature relationship rather than a fixed threshold — lower temperatures require longer exposure to achieve comparable conversion. Above approximately 150–160°C, volatile terpenes begin to degrade significantly alongside the decarboxylation reaction.
Is THCA the same as THC pharmacologically?: No. THCA and THC are structurally distinct molecules with different three-dimensional shapes. THCA does not interact with CB1 receptors in the same way THC does, due in part to its bulkier carboxyl group. Researchers study the acid and neutral forms separately, and neither should be assumed to have the same pharmacological properties as the other. Active investigation into the acid-form cannabinoids continues in the scientific literature.
Why does decarboxylation matter for manufactured medicinal cannabis products?: In regulated pharmaceutical manufacturing, decarboxylation is a documented, validated step in the production process. The TGA's Good Manufacturing Practice (GMP) framework requires that conditions be controlled and recorded, and finished products are analytically tested to confirm their cannabinoid profile. This is what allows batch-to-batch consistency. Some formulations intentionally retain a proportion of acid-form cannabinoids — that too is a deliberate manufacturing decision confirmed by testing.
Do all cannabinoids have acidic precursors that require decarboxylation?: Most of the major and minor cannabinoids do originate from acid-form precursors in the plant. CBDA converts to CBD, CBGA to CBG, and so on across the family. CBN is a notable exception — it is primarily an oxidative degradation product of THC rather than a direct decarboxylation product, and forms through a different pathway involving exposure to heat, light, and oxygen over time.